MedWatch

Pharmacosmos goes straight for rival in new phase III studies

The Danish pharmaceutical company Pharmacosmos has initiated a number of new phase III trials comparing the product Monofer to its main rival.

Foto: Pharmacosmos

Once again, the drug company Pharmacosmos has increased its bet on the company’s main asset Monofer against iron deficiency.

The company has enrolled the first patient for a group of three smaller phase III clinical trials to compare Monofer to its main rival Ferinject/Injectafer from the Swiss company Vifor Pharma (previously the Galencia Group).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier